AstraZeneca shares are on the rise this morning after the firm posted a strong set of financials for the second quarter and celebrated a recommendation for approval from US advisory panel for its bloodthinner Brilinta
|
Sanofi-Aventis has posted a solid set of figures for the second quarter this morning, but has lowered its full-year earnings forecast due to the introduction this week of generic Lovenox in the USA.
|
Bayer has posted a 1.3% dip in net income for the second quarter to 525 million euros this morning, but the Leverkusen-based firm’s turnover climbed 14.6% to 9.18 billion euros
|
Allowing American patients to use EU-approved medicines would increase regulatory competition, enable more patient choice and potentially save the lives of those suffering life-threatening illnesses who currently have no treatment options, says a new study.
|
Legal experts have been reacting to the news that France’s Servier has been accused by the European Commission of providing incorrect information during its recent inquiry into the pharmaceutical sector
|